{"disease":{"id":"muscle-invasive-bladder-urothelial-carcinoma","name":"muscle invasive bladder urothelial carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06167356","title":"Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05987241","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":992,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07097142","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT07322263","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Michael A. O'Donnell","has_results":false},{"nct_id":"NCT06020807","title":"Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Nucleix Ltd.","has_results":false},{"nct_id":"NCT04164082","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":161,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06770582","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07225205","title":"Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT07061964","title":"Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07302230","title":"Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05946369","title":"Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT06396533","title":"Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)","phase":"","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT07234968","title":"Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT06503614","title":"A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"John Sfakianos","has_results":false},{"nct_id":"NCT01031420","title":"Dose Dense MVAC for Muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":true},{"nct_id":"NCT05375903","title":"A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":false},{"nct_id":"NCT05406713","title":"Pembrolizumab in Muscle-invasive Bladder Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Matthew Galsky","has_results":false},{"nct_id":"NCT07279597","title":"A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07332351","title":"Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04047693","title":"Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Pusan National University Yangsan Hospital","has_results":false},{"nct_id":"NCT07064863","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Queen's University","has_results":false},{"nct_id":"NCT03914794","title":"A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT06257017","title":"Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Yung NA","has_results":false},{"nct_id":"NCT06204614","title":"Drug Screening Using IMD in Bladder Cancer","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06766266","title":"Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT05700227","title":"Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Varian, a Siemens Healthineers Company","has_results":false},{"nct_id":"NCT05564416","title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06443944","title":"An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"CG Oncology, Inc.","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}